ABSTRACT
Objective: Coronary revascularization is associated with better outcomes in coronary artery disease patients. We aim to investigate the prevalence, and factors associated with left ventricular (LV) improvement following successful percutaneous coronary intervention (PCI) of patients with impaired systolic function with specific reference to the value of baseline GLS. Methods: This retrospective study reviewed the records of coronary artery disease patients with impaired systolic function who were admitted and treated with PCI. Result: Out of 420 consecutive acute coronary syndrome patients with an impaired systolic function who were admitted and treated with PCI during the period from January 2021 to December 2021, 147 patients (35%) showed no improvement in the Left ventricular ejection fraction (LVEF) post PCI and 273 patients (65%) showed improvement of the LVEF post PCI in their follow up echocardiogram. Larger myocardial injury dilated LV dimension at the acute phase showed a strong impact on further improving LV systolic function. Baseline GLS showed a higher statistical difference between the Non-improving LVEF and improving LVEF groups. Moreover, the early GLS and further LV systolic function improvement were strongly correlated (P < 0.001) with higher sensitivity and specificity. A receiver operating characteristic curve (ROC) analysis demonstrated that GLS values greater than 9% are a predictor of significant LVEF improvement in the follow-up stage. Conclusion: Sizable proportion of patients with impaired systolic function following successful PCI show further LV systolic recovery. We demonstrated that the baseline GLS values of more than 9% are an accurate predictor of significant LVEF improvement
ABSTRACT
La insuficiencia cardiaca es considerada una de las enfermedades más prevalente de los últimos años. A pesar de los avances para su tratamiento con las nuevas drogas y dispositivos, como el cardiodesfibrilador implantable y la terapia de resincronización cardiaca, la progresión lleva a deterioro en la calidad de vida, frecuentes hospitalizaciones y altos porcentajes de mortalidad. En la etapa avanzada de esta enfermedad el trasplante cardiaco continua siendo de elección para su tratamiento, aunque no constituye la terapia adecuada para todos los pacientes. Muchos a la espera del mismo requieren soporte con drogas inotrópicas las cuales conllevan a deterioro progresivo y supervivencia limitada, cuando los tiempos de espera se prolongan o el trasplante no se realiza. Por esto, los avances en asistidores mecánicos permiten considerar a estos dispositivos como el tratamiento durante la espera del trasplante y como una alternativa en los cuales el trasplante no se considera una opción. Es nuestro objetivo realizar una revisión sobre los avances y la utilidad de los asistidores mecánicos en los pacientes con insuficiencia cardiaca avanzada, en los cuales la última opción es el trasplante cardiaco.
Heart failure is considering one of the most prevalent diseases in recent years. Despite advances in the treatment with new drugs and devices such as implantable defibrillator and cardiac resynchronization therapy, the progression in heart failure leads to deterioration in the quality of life, frequent hospitalizations and high mortality rates. Advanced stage of this disease remains heart transplantation for treatment choice, although is not the adequate therapy for all the patients. Many of them require support with inotropic drugs, which lead to a progressive deterioration and limited survival, because waiting times are prolonged or transplantation is not performed. Therefore, progress in circulatory support devices allow to consider these as the treatment while awaiting transplantation and an alternative when the transplant is not considered an option. It is our objective to review the progress and the usefulness of circulatory support devices in patients with advanced heart failure, in which the last option is heart transplantation.